Please note- The Diabetes Knowledge Centre is for Doctors and other Healthcare Professionals.

The prognosis of patients with diabetes is improved by interventions that reduce HbA1C which is influenced by both fasting and postprandial blood glucose levels. Using basal insulin analogues to manage blood glucose levels in patients with Type 2 diabetes is beneficial for a number of reasons.

Postprandial glucose represents a major contribution to overall hyperglycaemia and is important in the improvement of glycaemic control.  Postprandial hyperglycaemia per se is also an independent risk factor for adverse cardiovascular outcomes and complications of diabetes.

The IDF guidelines are easily available, and assist physicians in the diagnosis and management of diabetes.

Consequently, postprandial hyperglycaemia is an important clinical target in the treatment of diabetes mellitus, as is now recognised in all major treatment guidelines.

Reducing postprandial blood glucose excursions in patients with diabetes requires that their blood insulin concentrations are increased rapidly in the early prandial setting. However, the absorption properties of subcutaneously administered soluble human insulin are not ideal for achieving this goal.

Both oral and insulin therapies are available for the treatment

Analogues of human insulin, such as insulin aspart, have been engineered for more rapid absorption through reduced self-association properties, enabling a more satisfactory re-creation of the prandial insulin response.

Enter the Diabetes Knowledge Centre

What’s in the Diabetes Knowledge Centre?

• Screening & Diagnosis
• Lifestyle management
• Oral Agents
• Insulin Therapy
• Dual Action
• Short Term Action
• Product benefits
• References
• Suitable Devices
• In pump therapy
  
• The Need For Insulin Analogues
• Rationale
• IDF 2005